147 related articles for article (PubMed ID: 38161925)
1. Drug-Induced Hidradenitis Suppurativa: A Case Report.
Kisule A; Kak V; Alamelumangapuram C; Robinson C
Cureus; 2023 Nov; 15(11):e49637. PubMed ID: 38161925
[TBL] [Abstract][Full Text] [Related]
2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
3. Challenges in the Management of Perianal Hidradenitis Suppurativa in an African American Male: A Case Report.
Russell N; Kpughur-Tule N; Ravichandar E; Dorta Torres G; Tiesenga F
Cureus; 2023 Sep; 15(9):e45788. PubMed ID: 37872932
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.
Dumont LM; Landman C; Sokol H; Beaugerie L; Cosnes J; Seksik P; Guégan S;
Aliment Pharmacol Ther; 2020 Jul; 52(2):303-310. PubMed ID: 32525586
[TBL] [Abstract][Full Text] [Related]
5. Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn's Disease?
Beraldo RF; Marcondes MB; Baima JP; Barros JR; Ramdeen M; Saad-Hossne R; Sassaki LY
Clin Exp Gastroenterol; 2020; 13():293-298. PubMed ID: 32943900
[TBL] [Abstract][Full Text] [Related]
6. Two Cases of Paradoxical Hidradenitis Suppurativa while on Adalimumab.
Harvin G; Kasarala G
Case Rep Gastroenterol; 2016; 10(1):88-94. PubMed ID: 27403108
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.
Fotiadou C; Vakirlis E; Ioannides D
Clin Cosmet Investig Dermatol; 2016; 9():367-372. PubMed ID: 27799806
[TBL] [Abstract][Full Text] [Related]
8. A case of a patient with stage III familial hidradenitis suppurativa treated with 3 courses of infliximab and died of metastatic squamous cell carcinoma.
Scheinfeld N
Dermatol Online J; 2014 Mar; 20(3):. PubMed ID: 24656278
[TBL] [Abstract][Full Text] [Related]
9. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases.
Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M
J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416
[TBL] [Abstract][Full Text] [Related]
10. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.
Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
J Dermatol; 2022 Apr; 49(4):411-421. PubMed ID: 35040156
[TBL] [Abstract][Full Text] [Related]
11. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.
Diamantova D; Lomickova I; Cetkovska P
Acta Dermatovenerol Croat; 2014; 22(4):291-3. PubMed ID: 25580790
[TBL] [Abstract][Full Text] [Related]
13. Ustekinumab treatment for hidradenitis suppurativa.
Takeda K; Kikuchi K; Kanazawa Y; Yamasaki K; Aiba S
J Dermatol; 2019 Dec; 46(12):1215-1218. PubMed ID: 31638283
[TBL] [Abstract][Full Text] [Related]
14. Natural history, presentation, and diagnosis of hidradenitis suppurativa.
Micheletti RG
Semin Cutan Med Surg; 2014 Jun; 33(3 Suppl):S51-3. PubMed ID: 25188458
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy.
Samycia M; Brassard A
J Cutan Med Surg; 2013 Oct; 17 Suppl 1():S23-32. PubMed ID: 24144253
[TBL] [Abstract][Full Text] [Related]
16. Boils at Frictional Locations in a Patient with Hidradenitis Suppurativa.
Boer J; Mihajlovic D
Acta Dermatovenerol Croat; 2016 Dec; 24(4):303-304. PubMed ID: 28128084
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
[TBL] [Abstract][Full Text] [Related]
18. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
[TBL] [Abstract][Full Text] [Related]
19. A Controversial Relationship Between Crohn's Disease and Hidradenitis Suppurativa: A Case Series and Literature Review.
Buchanan F; Saleem S; Alsamman MA
Cureus; 2022 Mar; 14(3):e23422. PubMed ID: 35481292
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease.
Lukach AJ; Saul MI; Ferris LK; Swoger JM
Dig Dis Sci; 2018 Mar; 63(3):755-760. PubMed ID: 29357084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
